PDCD1 and non-small cell lung carcinoma: Immunotherapy with anti-PD-1/PD-L1 agents improve long-term survival in advanced NSCLC and is now considered a standard treatment either alone or with chemotherapy for metastatic NSCLC since 2016 [12].